STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo

CHEN HUANG1,2,3*, TAO JIANG1*, LIN ZHU1, JUN LIU1,2,3, JUN CAO1, KE-JIAN HUANG1 and ZHENG-JUN QIU1,2,3

1Department of General Surgery, Affiliated First People's Hospital, Shanghai Jiao Tong University, 200080 Shanghai; 2Shanghai Key Laboratory of Pancreas Disease, 200080 Shanghai; 3Pancreatic Cancer Center of Shanghai Jiaotong University, 200080 Shanghai, P.R. China

Received January 3, 2011; Accepted March 22, 2011

DOI: 10.3892/ijo.2011.1000

Abstract. Signal transducers and activators of transcription 3 (STAT3) is a central cytoplasmic transcription factor that is activated by phosphorylation in response to extracellular signals and oncogenes. STAT3 regulates a number of pathways important in tumorigenesis including cell cycle progression, apoptosis, tumor angiogenesis, invasion and metastasis, and tumor cell evasion of the immune system. Our studies demonstrated that constitutively activated STAT3 plays an important role in the angiogenesis of pancreatic cancer. The objective of this study was to evaluate the potential use of RNA interference (RNAi) to knock down the STAT3 gene and the effect on angiogenesis of human pancreatic cancer cells in vitro and in vivo. We stably inhibited the expression of STAT3 and phosphorylated STAT3 (p-STAT3) using RNAi in the SW1990 pancreatic cancer cell line. Furthermore, RNAi for STAT3 inhibited STAT3-induced HUVEC cell migration and cell proliferation, and significantly suppressed the levels of secreted vascular endothelial growth factor (VEGF) and matrix metalloproteinases-2 (MMP-2) of SW1990 cells. In vivo experiments showed that RNAi for STAT3 significantly suppressed tumor growth and angiogenesis of SW1990 cells. Furthermore, silencing the STAT3 gene in SW1990 cells by RNAi also led to a decrease of VEGF and MMP-2 at the mRNA and protein levels. Collectively, these results demonstrate that the STAT3 signaling pathway plays an important role in the angiogenesis of pancreatic cancer and that knockdown of the STAT3 gene using the RNAi technique may be a novel therapeutic option for the treatment of pancreatic cancer.

Introduction

Pancreatic cancer is the fourth most common cause of adult cancer death, accounting for an estimated 42,470 new cases and 35,240 deaths in USA for 2009 (1). The high mortality rate is due to the aggressive biological properties, late onset of symptoms and the failure of systemic therapies (2). Of all the treatments used against pancreatic cancer, radical surgery is still the only one that can completely eradicate this disease (3). However, in only 5-25% of the patients presenting with pancreatic cancer will the tumor be operable. Even after curative resection, the actual 5-year survival is only 10-20% (4). Unfortunately, effective systemic therapy capable of reversing the aggressive nature of this disease is currently not available and the specific molecular regulatory pathways involved in pancreatic cancer initiation and progression have not been fully characterized.

Angiogenesis plays important roles in many developmental and pathological processes including tumor growth and metastasis. It has been well established that all successful tumors must undergo neovascularization, or angiogenesis, in order to acquire nutrients for continued growth and metastatic spread. Without angiogenesis, a solid tumor rarely grows larger than 2 to 3 mm (5).

Abundant angiogenesis regulators and activation of oncogene are essential for an angiogenesis phenotype that supports tumorigenicity (6). Although numerous angiogenesis regulators or oncogenes are involved, signal transducers and activators of transcription 3 (STAT3) play a pivotal role in tumor angiogenesis (7-9). STAT3, a member of the signal transduction and activation of transcription family, is a key cytoplasmic transcription factor activated by tyrosine kinase growth factor and cytokine receptors. Once tyrosine is phosphorylated, two STAT3 mono-mers form dimers through reciprocal phospho-tyrosine-SH2 interactions, and translocate to the nucleus where they bind to STAT3-specific DNA-response elements of angiogenesis-related target genes, and induce angiogenesis-related target gene transcription (10,11).

Many researchers have proved that the angiogenesis-related gene such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases-2 (MMP-2) are the target genes of STAT3 and STAT3 and could promote tumor angiogenesis and metastasis through upregulating the expression of VEGF (7-9)
and MMP-2 (12,13). Our previous studies demonstrated that overexpression of STAT3, p-STAT3, VEGF and MMP-2 was found in pancreatic cancer and the expression of p-STAT3 was positively correlated with VEGF and MMP-2 (14-16). Taken together, these data indicate that STAT3 is associated with angiogenesis and metastasis through upregulating angiogenesis-related genes in pancreatic cancer, and inhibition of the expression or function of STAT3 may improve the disease outcome.

The present study was designed to evaluate the potential use of RNA interference (RNAi) to knock down STAT3 expression and activation and the effect on the angiogenesis of human pancreatic cancer cells in vitro and in vivo. The angiogenesis phenotypic changes resulting from the reduction of STAT3 expression were studied both in vitro and in vivo. We found that knockdown of the STAT3 gene by RNAi significantly suppressed the expression of VEGF and MMP-2, which was accompanied by marked inhibition of STAT3 induced HUVEC cell migration and cell proliferation in vitro and tumor cell angiogenesis in vivo. Our results demonstrate that STAT3 signaling pathway plays important roles in angiogenesis of pancreatic cancer and that knockdown of STAT3 gene using RNAi technique may be a novel therapeutic option for treatment of pancreatic cancer.

Materials and methods

Cell lines and culture conditions. Human pancreatic cancer cell line SW1990 was purchased from American Type Culture Collection. They were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator at 37°C. Human umbilical vein endothelial cells (HUVEC) were purchased from American Type Culture Collection. They were maintained in DMEM supplemented with 10% fetal calf serum, 2 mmol/l glutamine, HAT (hypoxanthine 0.1 mmol/l, aminopterin 0.4 mmol/l, thymidine 16 mmol/l), 100 units/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator with an atmosphere of 5% CO₂-95% air at 37°C. Human umbilical vein endothelial cells (HUVEC) were purchased from American Type Culture Collection. They were maintained in DMEM supplemented with 10% fetal calf serum, 2 mmol/l glutamine, HAT (hypoxanthine 0.1 mmol/l, aminopterin 0.4 mmol/l, thymidine 16 mmol/l), 100 units/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator with an atmosphere of 5% CO₂-95% air at 37°C.

Transfection. In our previous studies, we constructed three STAT3 specific siRNA expression vectors (pRNAT-STAT3-siRNA-I, II, III) and proved pRNAT-STAT3 siRNA-II had the most obvious gene silencing effect (17). We also constructed a negative control scrambled siRNA expression vector (pRNAT-Con). For stable transfection, SW1990 cells were transfected with pRNAT-STAT3-RNAi-II plasmid which had the most obvious gene silencing effect. SW1990 cells were also transfected with the pRNAT-Con vector. Cells were then selected with a standard medium containing 500 mg/ml G418 (Gibco, USA) for 14 days. pRNAT-Con and pRNAT-STAT3-RNAi-II expression vector were carried out in SW1990 cells, and G418-resistant colonies were pooled to establish stable SW1990 pRNAT-Con transfectants (SW1990-Con) and SW1990 STAT3-RNAi transfectants (SW1990-RNAi). The stable transfection cells were then used for subsequent studies.

Cell migration assay. Transwells (Costar, Cambridge, MA) were pretreated with serum-free medium at 37°C for 1 h before seeding with HUVECs at 1x10³ per well in 100 µl endothelial basal medium with 0.1% fetal bovine serum. The transwells were then inserted into 24-well plates containing 600 µl conditioned medium and incubated at 37°C for 6 h to allow HUVEC cells to migrate. Cells on the upper side of the filter were removed with cotton swabs. Migrated cells on the lower side of the filter were fixed and stained with HE. The number of migrated cells was counted under a binocular microscope.

Cell proliferation assay. Cultured supernatants from SW1990, SW1990-Con and SW1990-RNAi cells were collected. The metabolic activity of HUVEC cells was determined by methyl thiazoliterazolium (MTT) assay. Briefly, exponentially growing HUVEC cells (2.5x10⁵) were seeded in 96-well culture plates in culture medium at an optimal density. After 24 h, the medium was changed to conditioned medium from SW1990, SW1990-Con and SW1990-RNAi cells. MTT assays were performed after 1, 2 and 3 days of conditioned medium treatment. At the time of the assay, the cells were stained with 20 µl MTT (5 mg/ml) (Sigma, USA) at 37°C for 4 h and subsequently solubilized in 150 µl of DMSO. OD readings were obtained at 570 nm. The cell growth rate was represented by the relative ratio of OD570 at 24, 48, and 72 h, to OD570 at 0 h, respectively. The growth curve was drawn according to the cell growth rate.

Cell cycle assay. HUVEC were collected and fixed after 48 h culture with conditioned medium from SW1990, SW1990-Con and SW1990-RNAi cells. After incubation in RNase A for 30 min at 37°C, the cells were stained with propidium iodide (PI). Flow cytometric analysis was done using a FACScan instrument (Becton-Dickinson, Mountain view, CA) and CellQuest software.

Enzyme-linked immunosorbent assay (ELISA). SW1990, SW1990-Con and SW1990-RNAi cells were seeded into 24-well plates. Fresh medium was added after overnight culture. The cultured supernatants were collected 24 h later and centrifuged to eliminate cellular fragments. VEGF and MMP-2 protein accumulated in the culture medium were analyzed using sandwich ELISA, wherein the supernatant of the culture was incubated with VEGF antibody (goat polyclonal anti-human VEGF, Santa Cruz, USA), MMP-2 antibody (goat polyclonal anti-human MMP-2, Santa Cruz, USA) and streptavidin alkaline phosphatase (Santa Cruz). The antigen-antibody complex was then incubated with p-nitrophenyl phosphate (Sigma) and dissolved in pNPP buffer (Chemicon, USA). MMP-2 and VEGF concentrations in the samples were determined from the absorbance at 570 nm spectrophotometrically.

Eggs and animals. Fertile eggs were acquired from Merial Vital Laboratory Animal Technology Company (Beijing, China). After washing the outsides of the shells with soap and saturating in a 70% ethyl alcohol bath for 30 sec, the fertile eggs were incubated in an incubator with an atmosphere of 5% CO₂-95% air at 37°C and 60% relative humidity and rotated 180° three times daily. Male athymic BALB/c nude mice were obtained from the Animal Center of Chinese Academy of Science (Shanghai, China) and housed in laminar flow cabinets under specific pathogen-free conditions. The mice were used when they were 6-8 weeks old. The use of eggs and animals in this study complies with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 86-23, revised...
and the current Chinese regulations and standards on the use of Laboratory Animals.

Chick embryo chorioallantoic membrane (CAM) assay. The CAM model used in these studies was carried out according to the procedure described by Storgard et al (18) and Xu et al (19). In brief, eggs were candled using a hand held-egg candler at the blunt end of the egg to identify the air sac and prominent blood vessels after incubating for 9 days. Using a mini drill, the CAM was separated from the shell by making a shallow burr hole at the blunt end on the egg and another burr hole made perpendicular to the previously identified blood vessels in the center of the egg. Mild suction was applied to the blunt end burr hole to displace the air sac and drop the CAM away from the shell. Fine forceps were then used to pick away the shell over the air sac, so that a window could be made and the CAM identified. SW1990, SW1990-Con and SW1990-RNAi cells (in a total volume of 100 µl, 1.0x10^7 cells) were transplanted on the CAM in an avascular area under sterile conditions. The window was sealed with sterile scotch tape and the egg returned to the incubator. On day 9 of inoculation, the tapes were removed and digital images of the live CAM were captured using a dissection microscope and a colour video camera. Next, the tumor volume (a^2xbx0.4, where a represents the longer axis and b represents the shorter axis) was measured (19).

In vivo tumorigenicity assay. Six-to-eight-week-old male athymic BALB/c nude mice were housed in laminar flow cabinets under specific pathogen-free conditions. SW1990 cells and stable transfection cells (SW1990-Con, SW1990-RNAi) were injected into the right flank of mice in a total volume of 100 µl (1.0x10^7 cells). The tumor-bearing mice were sacrificed 35 days after inoculation and the tumor were removed and weighed. Then, the tumor tissue was fixed in formalin, embedded in paraffin, cut into 5 µm sections, and stained with HE.

Microvessel counting. Tissue sections stained with CD34 were used for evaluating MVD. Immunohistochemical staining was performed as follows: formalin-fixed paraffin-embedded tissue sections of 5 µm thickness were dewaxed in 100% xylene and rehydrated by serial incubations in 100, 90 and 80% ethanol, followed by phosphate-buffered saline (PBS). Antigen retrieval was performed by microwaving slides in 10 mM sodium citrate buffer (pH 6.0) for 1 min at full power followed by 9 min at medium power, according to the manufacturer's instructions. To inactivate the endogenous peroxidase activity, sections were treated with freshly prepared 0.3% (vol/vol) hydrogen peroxide in methanol in dark, for 30 min, at room temperature (RT). Non-specific antibody binding was then blocked with 5% goat serum in PBS for 90 min at RT. The sections were then incubated with rabbit anti-human CD34 polyclonal antibody (Santa Cruz) or rabbit polyclonal IgG controls (Vector Laboratories, USA) in blocking buffer overnight at 4˚C. The sections were then rinsed in wash buffer (PBS containing 0.5% bovine serum albumin, 0.1% Tween-20) and incubated for 30 min with biotinylated goat anti-rabbit IgG (ABC staining kit, Santa Cruz) diluted according to the manufacturer's protocol. To inactivate the endogenous peroxidase activity, sections were treated with freshly prepared 0.3% (vol/vol) hydrogen peroxide in methanol in dark, for 30 min, at room temperature (RT). Non-specific antibody binding was then blocked with 5% goat serum in PBS for 90 min at RT. The sections were then incubated with rabbit anti-human CD34 polyclonal antibody (Santa Cruz) or rabbit polyclonal IgG controls (Vector Laboratories, USA) in blocking buffer overnight at 4˚C. The sections were then rinsed in wash buffer (PBS containing 0.5% bovine serum albumin, 0.1% Tween-20) and incubated for 30 min with biotinylated goat anti-rabbit IgG (ABC staining kit, Santa Cruz) diluted according to the manufacturer's protocol. Next, a solution of avidin-conjugated horseradish peroxidase (ABC staining kit) was applied for 30 min, according to the manufacturer's instruction. Peroxidase activity was developed in 0.5% (vol/vol) 3,3’-diaminobenzidine hydrochloride (DAB, Sigma) in PBS containing 0.03% (vol/vol) hydrogen peroxide for 2 min. Sections were counterstained with Harris’ hematoxylin.
and mounted in gelatin (Sigma, USA). Then the slides were examined under x100 magnification for the hot spots rich in vessels and MVDs were counted under x400 magnification, so that every single brown-stained cell and cell cluster was calculated as a blood vessel, regardless of whether a vessel lumen structure was seen. Five different fields were chosen on each of the slides, and the stained vessels were counted simultaneously by 2 researchers under a microscope. The average of the 5 areas was recorded as the MVD score (20).

**RT-PCR.** Total RNA extraction from tumor cells was performed with TRIzol Reagent (Life Technologies, USA). Then, 2 µg of total RNA were reverse-transcribed with the First Strand cDNA Synthesis kit (Promega, USA) to synthesize cDNA samples. Subsequently, 2 µl of cDNA product was then subjected to PCR amplification with Taq DNA polymerase (Sangon, China) on a thermal cycler using the following primers. The oligo-nucleotide primers for STAT3 were constructed under the help of primer-design software ‘Primer Premier 5.0’. The oligo-nucleotide primers for MMP-2, VEGF and β-actin were constructed on the basis of the published sequence. The PCR primers used to detect each factor were as follows: VEGF, sense strand 5'-CCTGGTGATCCACATCTGC-3', with a product length of 838 bp (23). The PCR conditions were as follows: one cycle of denaturing at 94°C for 5 min, followed by 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, before a final extension at 72°C for 10 min. The PCR products were loaded onto 2% agarose gels and visualized with ethidium bromide under UV light. This experiment was performed three times and representative data are shown.

**Western blot analysis.** Whole-cell protein extracts and Nuclear protein extracts from tumor cells were prepared with RIPA Lysis Buffer (Santa Cruz, USA) and Nuclear Extract kit (Active Motif), according to the manufacturer's instructions, respectively. Protein concentrations were determined using a Bio-Rad assay kit (Bio-Rad, USA). Lysates containing 100 µg of protein were mixed with loading-buffer with 5% β-mercaptoethanol, and heated for 5 min at 100°C. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes by semi-dry blotting. Membranes were incubated in blocking buffer (1X TBS, 0.1% Tween 20, and 5% non-fat dry milk) for 1 h at room temperature, followed by hybridization with anti-p-STAT3 [tyr-705] antibody (Cell Signal, USA, 1:1000 dilution), anti-STAT3 antibody (Cell Signal, 1:1000 dilution), anti-VEGF antibody (Santa Cruz, 1:1000 dilution), anti-MMP-2 antibody (Santa Cruz, 1:1000 dilution) or anti-β-actin antibody (Labvision, USA, 1:100 dilution), at 4°C overnight. After three washes in TBS/0.1% Tween 20, the membranes were hybridized with a horseradish peroxidase-conjugated secondary antibody
rabbit IgG (Santa Cruz, 1:5000 dilution) for 1 h at room temperature. After three washes in TBS/0.1% Tween 20, signals were detected by chemiluminescence using the Western Blotting Luminol Reagent (Santa Cruz, USA). The experiments were performed three times and representative data are shown.

Results

Silencing of STAT3 expression by stable transfection of STAT3 specific shRNA expression vector. Total and nuclear protein extracts were prepared from parental SW1990, pRNAT-Con and SW1990-RNAi cells, and the levels of STAT3 and p-STAT3 protein expression in these cells were determined by Western blotting. Densitometric measurements indicated that the levels of STAT3 and p-STAT3 protein expression in the transfectants containing pRNAT-STAT3-siRNA-II (SW1990-RNAi) were decreased 92.3 and 90.1% as compared to parental SW1990 cells (Fig. 1). The result indicated that table transfection of pRNAT-STAT3-siRNA-II vector silenced STAT3 expression.

Effect of STAT3 small interfering RNA on secreted VEGF and MMP-2 protein expression. ELISA was performed using human VEGF-specific antibody and MMP-2-specific antibody to quantify the amount of VEGF and MMP-2 protein in the culture media. When cells were transfected with pRNAT-STAT3-siRNA-II, the VEGF concentration in the media was decreased significantly (Table II) compared with cells transfected with pRNAT-Con or parental SW1990 cells (P<0.05). A similar inhibitory effect on MMP-2 protein levels is shown in Table II, which demonstrated that the expression of MMP-2 protein in the culture medium of SW1990 cells was also significantly inhibited after STAT3 silencing. These results indicated that silence of STAT3 gene suppressed secreted VEGF and MMP-2 protein expression.

Effect of STAT3 small interfering RNA on pancreatic cancer growth and angiogenesis in the CAM model. To determine whether inhibition of STAT3 by siRNA had an effect on tumor growth and angiogenesis, SW1990, SW1990-Con and SW1990-RNAi cells were transplanted on the CAM in an avascular area under sterile conditions. All fertile eggs (six of six) developed tumors from parental SW1990 cells or SW1990-Con cells without significant difference in tumor volume. In contrast, only four of six fertile eggs developed tumors from SW1990-RNAi cells and the tumors were significantly smaller than those of control mice (P<0.05). Tumors from SW1990 and SW1990-Con cells appeared highly vascularized. On the contrary, when the SW1990-RNAi cells were implanted in vivo, a robust decrease in vascularization was observed.

Effect of STAT3 small interfering RNA on pancreatic cancer growth and angiogenesis in the nude mouse model. To determine whether inhibition of STAT3 by siRNA had an effect on tumor growth and angiogenesis, SW1990, SW1990-Con and SW1990-RNAi cells were inoculated s.c. into nude mice. The six mice (6/6) developed tumors from parental SW1990 cells or SW1990-Con cells without significant difference in tumor volume. In contrast, only four of six fertile eggs developed tumors from SW1990-RNAi cells and the tumors were significantly smaller than those of control mice (Fig. 3A). Tumors from SW1990 and SW1990-Con cells induced abundant neovessels around the tumor body. On the contrary, when the SW1990-RNAi cells were implanted in vivo, a robust decrease in vascularization was observed (Fig. 3B).
SW1990-Con cells without significant difference in tumor weight. In contrast, only three of six mice developed tumors from SW1990-RNAi cells and the tumors were significantly smaller than those of the control mice (Fig. 4A). Tumors from SW1990 and SW1990-Con cells appeared highly vascularized. On the contrary, when the SW1990-RNAi cells were implanted in vivo, a robust decrease in vascularization was observed (Fig. 4B). Next, we checked the MVD changes of tumors after inhibition of STAT3 in vivo. As shown in Fig. 5A and B, CD34-positive vessels were abundant in SW1990 and SW1990-Con tumors. MVD was significantly decreased in tumors formed by SW1990-RNAi. The MVD in tumors treated with SW1990-Con was similar to that observed in the SW1990 tumors.

**Effect of STAT3 small interfering RNA on VEGF and MMP-2 expression of SW1990 cells.** STAT3 activation contributes to oncogenesis through regulation of its target genes. To determine the effect of downregulation of STAT3 on angiogenesis-related target gene expression, we assayed for the expression of VEGF and MMP-2 by RT-PCR both of which are directly involved in tumor angiogenesis. As shown in Fig. 6A, the expression of VEGF and MMP-2 mRNAs in SW1990 cells were significantly inhibited after STAT3 silencing. The densitometric analyses revealed VEGF relative expression of SW1990-RNAi cells was reduced to 46% of that of parental SW1990 cells. And MMP-2 relative expression of SW1990-RNAi cells was reduced to 28% of that of parental SW1990 cells. A similar inhibitory effect on protein levels is shown in Fig. 6B. These results demonstrated that blockade of STAT3 signaling was able to inhibit SW1990 cell angiogenesis potential by downregulating VEGF and MMP-2.
STaT3 is a key signal transduction protein that mediates signaling by numerous cytokines, peptide growth factors, oncoproteins and plays important roles in cancer progression (24,25). Several studies have shown that STaT3 is abundantly expressed in pancreatic cancer tissues and cells (26,27). In our previous studies, we demonstrated that overexpression of STaT3, p-STaT3, VEGF and MMP-2 was found in pancreatic cancer and the expression of p-STAT3 was positively correlated with VEGF and MMP-2 (14-16). In the present study, we proved that STaT3 played an important role in the angiogenesis of pancreatic cancer by selectively inhibiting STaT3 expression using plasmid vector-based RNAi.

RNAi represents a key gene therapy technique in mammalian systems. Compared with traditional gene therapy methods, RNAi possesses the advantages of exquisite precision and high efficacy in downregulating gene expression, thus providing a new approach to the treatment of diseases including cancer (28,29). Delivery of siRNA can be achieved through exogenous application of enzymatically or chemically synthesized siRNA or through endogenous expression using plasmid or viral vector delivery system. Enzymatically or chemically synthesized siRNA is costly and has been shown to have a relatively short half-life with only transient inhibition of the target gene because of its instability and limited duration of interference. But, plasmid or viral vector-based siRNA technology has some advantages over enzymatically or chemically synthesized siRNA. Firstly, vector-based RNAi induces more efficient and stable RNA interference. Moreover, vector-based RNAi permits co-expression of reporter genes such as GFP or luciferase, which facilitates tracking and selection of transfected cells (30,31).

In the present study, we used plasmid vector-based RNAi targeting STaT3 to silence the expression of STaT3 in human pancreatic cancer cells SW1990. We successfully constructed the recombinant plasmid pRNAT-STAT3-RNAi-II (14) and employed the recombinant plasmid to generate SW1990-RNAi cell line, which showed a significantly decreased STaT3 expression. Attenuation of STaT3 changed the angiogenesis behavior of human SW1990 cells in vitro and in vivo. In vitro assay revealed targeting STaT3 by RNAi inhibited STaT3 induced HUVEC cell migration, cell proliferation and arrested HUVEC cells at G1/G0 phase. Moreover, targeting STaT3 by RNAi inhibited tumor growth and angiogenesis of SW1990 cells in vivo with CAM and the nude mouse tumor xenograft model.

Angiogenesis is the formation of new blood vessels from pre-existing ones, which consists of several steps: endothelial cell (EC) proliferation, migration, basement membrane degradation, and new lumen organization (32). It has been demonstrated that abundant genes play important roles in tumor angiogenesis. The inhibitory mechanism in the angiogenesis after STaT3 silencing with RNAi is considered as downregulation of these genes related with tumor angiogenesis. Vascular endothelial growth factor (VEGF) is one of the most important of the known angiogenic mitogens (33,34). Previous studies have demonstrated that VEGF is associated with poor survival and prognosis for pancreatic cancer. Furthermore, it has been correlated with the increase in the microvessel density (MVD), angiogenesis, local invasion and liver metastasis (35-37). A recent study has reported that VEGF is a downstream target gene of STaT3 and stable transfection of dominant-negative STaT3 (DN-STAT3) decreases VEGF expression of the pancreatic cancer cell line FG (8,9). In this study, we also found that the silencing of STaT3 significantly decreased the mRNA and protein expression of VEGF in SW1990 cells. Tumor angiogenesis also needs degradation of extracellular matrix (ECM) besides angiogenic mitogens to form new blood vessels. Matrix metalloproteinases (MMPs) constitute a family of secreted, zinc-dependent endopeptidases that are required for ECM degradation in a variety of physiological and pathological tissue remodeling processes, including tumor angiogenesis, invasion and metastasis (38). Recently, some studies have found that STaT3 signaling directly regulates MMP-2 expression in melanoma cells and proved MMP-2 to be a target gene of STaT3 (12,13). In our present study, the silencing of STaT3 also reduced the mRNA and protein expression of MMP-2 in SW1990 cells.

### Table I. Effects of silence of STaT3 gene on STAT3 induced HUVEC cell cycle.

<table>
<thead>
<tr>
<th>Group</th>
<th>G0/G1 (%; mean ± SD)</th>
<th>S (%; mean ± SD)</th>
<th>G1/M (%; mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW1990</td>
<td>65.96±5.52</td>
<td>16.59±1.92</td>
<td>17.45±1.34</td>
</tr>
<tr>
<td>SW1990-Con</td>
<td>68.08±5.98</td>
<td>16.61±1.87</td>
<td>15.31±1.03</td>
</tr>
<tr>
<td>SW1990-RNAi</td>
<td>80.95±7.49*</td>
<td>4.57±0.87*</td>
<td>14.48±1.29</td>
</tr>
</tbody>
</table>

*P<0.05 compared with control.

### Table II. Effects of silence of STaT3 gene on secreted VEGF and MMP-2 protein in SW1990 cells.

<table>
<thead>
<tr>
<th>Group</th>
<th>VEGF (pg/ml)</th>
<th>MMP-2 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW1990</td>
<td>38.76±4.64</td>
<td>29.47±3.52</td>
</tr>
<tr>
<td>SW1990-Con</td>
<td>40.12±5.12</td>
<td>26.53±3.15</td>
</tr>
<tr>
<td>SW1990-RNAi</td>
<td>15.39±5.83*</td>
<td>9.88±2.98*</td>
</tr>
</tbody>
</table>

*P<0.05 compared with control.

### Discussion

STAT3 is a key signal transduction protein that mediates signaling by numerous cytokines, peptide growth factors, oncoproteins and plays important roles in cancer progression (24,25). Several studies have shown that STAT3 is abundantly expressed in pancreatic cancer tissues and cells (26,27). In our previous studies, we demonstrated that overexpression of STAT3, p-STAT3, VEGF and MMP-2 was found in pancreatic cancer and the expression of p-STAT3 was positively correlated with VEGF and MMP-2 (14-16). In the present study, we proved that STAT3 played an important role in the angiogenesis of pancreatic cancer by selectively inhibiting STAT3 expression using plasmid vector-based RNAi.
In conclusion, the present study indicates that RNAi targeting STAT3 via a plasmid vector-based system effectively sustains the silence of STAT3 gene expression in SW1990 cells. The impaired STAT3 expression results in reduced SW1990 cell angiogenesis in vitro and in vivo through downregulation the expression of VEGF and MMP-2. Targeting STAT3 expression and activation with RNAi may be a potential therapeutic strategy in the treatment of pancreatic cancer.

Acknowledgements

This study was supported by a grant (No. 09QA1404600) awarded by fund for scientific research of Science and Technology Commission of Shanghai Municipality and a grant (No. 0801) awarded by fund for scientific research of Affiliated First People’s Hospital of Shanghai Jiao Tong University. We thank Dr Wei Qiu and Dr Ming Xu for providing technical assistance.

References